T1D RELAY
Volunteers
Health Professionals
What is the purpose of this trial?
TrialNet is studying the use of rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extends insulin production in people newly diagnosed with type 1 diabetes (T1D).
Previous studies with similar treatments showed people can make more insulin for a longer period of time while receiving either of the treatments. T1D RELAY will study if two treatments consecutively performs better than rituximab-pvvr alone. Researchers will test if those who are also treated with abatacept have better C-peptide levels over time.
- Trial withNational Institute of Diabetes and Digestive & Kidney Diseases (NIDDK)
- Ages8 years and older
- GenderBoth
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Last Updated09/04/2024
- Study HIC#2000025525